MCID: HMN014
MIFTS: 55

Human Immunodeficiency Virus Infectious Disease

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 12 15
Hiv Infections 15

Classifications:



External Ids:

Disease Ontology 12 DOID:526
ICD9CM 34 042-042.99
MeSH 43 D015658
NCIt 49 C3108
SNOMED-CT 67 86406008
ICD10 32 B20
UMLS 71 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary : Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to human immunodeficiency virus type 1 and aids dementia complex. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lercanidipine and Candesartan cilexetil have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are cellular and hematopoietic system

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1856)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 34.1 TNF ITIH4 IL7 IL2 IL10 IFNG
2 aids dementia complex 33.6 TNF ITIH4 CXCR4 CXCL12 B2M
3 burkitt lymphoma 33.4 TNF IL7 IL10 IFNA1 CCL3
4 cervical cancer 33.3 TNF IL7 IL2 IL10 IFNG CXCR4
5 epidermodysplasia verruciformis 1 33.2 IL7 CXCR4 CD4
6 acquired immunodeficiency syndrome 33.0 TNF ITIH4 IL2 IL10 IFNG IFNA1
7 macs syndrome 32.8 TNF IL10 IFNG IFNA1 CD4
8 syphilis 32.7 TNF IFNG CD4 CD209 CCR5 B2M
9 candidiasis 32.6 TNF IL2 IL10 IFNG
10 toxoplasmosis 32.4 TNF IL10 IFNG CCR5 CCL3
11 diarrhea 32.4 TNF IL2 IL10 IFNG IFNA1
12 hepatitis c 32.3 TNF IL10 IFNG IFNA1 CCR5
13 pulmonary tuberculosis 32.3 TNF IL2 IL10 IFNG CCL4 CCL3
14 leishmaniasis 32.3 TNF IL2 IL10 IFNG CCR5
15 cryptococcosis 32.2 TNF IL10 IFNG CD4
16 exanthem 32.2 TNF IL2 IL10 IFNG IFNA1 CD4
17 chlamydia 32.2 TNF IL10 IFNG
18 pneumocystosis 32.2 TNF CD4 CCR5
19 bacterial pneumonia 32.2 TNF IL10 CD4 CCL3
20 lymphoma 32.2 IL2 IL10 CXCR4 CD38 CCR5 B2M
21 viral hepatitis 32.2 TNF IL2 IL10 IFNG IFNA1
22 pneumonia 32.1 TNF IL2 IL10 IFNG IFNA1 CCL5
23 bacterial infectious disease 32.1 TNF ITIH4 IL10 IFNG CD4 CCL4
24 visceral leishmaniasis 32.1 TNF IL2 IL10 IFNG
25 herpes zoster 32.1 TNF IL2 IL10 IFNG IFNA1 CD4
26 histoplasmosis 32.1 TNF IFNG CD4
27 meningitis 32.1 TNF IL2 IL10 IFNG CXCL12 CCL5
28 neutropenia 32.1 TNF IL2 IL10 IFNG IFNA1 CXCR4
29 cytomegalovirus infection 32.1 TNF CCL5 CCL3 B2M
30 peripheral nervous system disease 32.1 TNF IL2 IL10 IFNG CD4 B2M
31 chickenpox 32.0 TNF IL2 IL10 IFNG IFNA1 CD4
32 lymphopenia 32.0 IL7R IL7 IL2 IL10 IFNG B2M
33 hepatitis a 32.0 TNF IL10 IFNG IFNA1
34 measles 32.0 TNF IL2 IFNG IFNA1 CD209 CCL5
35 cytomegalovirus retinitis 32.0 TNF IL10 IFNG CXCL12 CD9 CD4
36 mycobacterium tuberculosis 1 32.0 TNF IL7 IL10 IFNG CXCR4 CD4
37 lung disease 32.0 TNF IL10 IFNG CXCR4 CCR5 CCL5
38 secondary syphilis 32.0 CD4 CD209 CCR5
39 tetanus 31.9 TNF IL7R IL2 IL10 IFNG
40 allergic hypersensitivity disease 31.9 TNF IL2 IL10 IFNG CD4 CCL5
41 progressive multifocal leukoencephalopathy 31.9 TNF IL2 CD4
42 thrombocytopenia 31.9 TNF IL7 IL2 IL10 IFNG IFNA1
43 herpes simplex 31.9 TNF IFNA1 CD209 CCL5
44 lymphadenitis 31.9 TNF IL10 IFNG CD4 CD209
45 lymphoma, non-hodgkin, familial 31.9 TNF IL7 IL2 IL10 CXCR4 CXCL12
46 genital herpes 31.9 IL10 CD4 CCR5 CCL5
47 gingivitis 31.9 TNF IL2 IL10 IFNG CCL5
48 extrapulmonary tuberculosis 31.9 TNF IL10 IFNG CD4
49 multidrug-resistant tuberculosis 31.8 TNF IL10 IFNG CD4
50 meningoencephalitis 31.8 TNF IL10 CD4 CCL5 B2M

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 B2M CCR5 CD38 CD4 CD9 CXCL12
2 hematopoietic system MP:0005397 10.21 B2M CCL5 CCR5 CD38 CD4 CD9
3 endocrine/exocrine gland MP:0005379 10.18 B2M CD38 CD4 CD9 CXCR4 IFNG
4 immune system MP:0005387 10.17 B2M CCL5 CCR5 CD38 CD4 CD9
5 digestive/alimentary MP:0005381 10.03 B2M CCR5 CD4 CXCR4 IFNG IL10
6 liver/biliary system MP:0005370 9.86 B2M CCR5 CXCL12 IFNG IL10 IL2
7 neoplasm MP:0002006 9.85 B2M CCR5 CD9 CXCR4 IFNG IL10
8 no phenotypic analysis MP:0003012 9.5 CD4 CXCL12 IFNG IL10 IL2 IL7
9 reproductive system MP:0005389 9.32 B2M CCR5 CD9 CXCL12 CXCR4 IFNG

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 747)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
2
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
3
Methadone Approved Phase 4 76-99-3 4095
4
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
5
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
6
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
7
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Indinavir Approved Phase 4 150378-17-9 5362440
11
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
12
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
17
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
18
Fosamprenavir Approved Phase 4 226700-79-4 131536
19
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
20
Echinacea Approved, Experimental Phase 4
21
Famotidine Approved Phase 4 76824-35-6 3325
22
Lumefantrine Approved Phase 4 82186-77-4 6437380
23
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
24
leucovorin Approved Phase 4 58-05-9 6006 143
25
Sulfamethoxazole Approved Phase 4 723-46-6 5329
26
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
27
Atovaquone Approved Phase 4 95233-18-4 74989
28
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
29
Proguanil Approved Phase 4 500-92-5 4923
30
Zoledronic Acid Approved Phase 4 118072-93-8 68740
31
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
32
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
33
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
34
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
35
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
36
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
37
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
38
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
39
Temazepam Approved, Investigational Phase 4 846-50-4 5391
40
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
41
carbamide peroxide Approved Phase 4 124-43-6
42
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
43
Lithium carbonate Approved Phase 4 554-13-2
44
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
45
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
46
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
47
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
48
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
49
Lopinavir Approved Phase 4 192725-17-0 92727
50
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096

Interventional clinical trials:

(show top 50) (show all 4430)
# Name Status NCT ID Phase Drugs
1 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
2 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
3 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
4 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
5 Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults Unknown status NCT03041051 Phase 4
6 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
7 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
8 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
9 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
10 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
11 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
12 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
13 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
14 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
15 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
16 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
17 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
18 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
19 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial. Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
20 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
21 A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone Unknown status NCT02354053 Phase 4 Switch to Triumeq
22 Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual) Unknown status NCT03447873 Phase 4 Continue with triple therapy;Switch to DTG + 3TC;Switch to DRV/cobicistat + 3TC
23 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
24 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
25 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
26 Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml Unknown status NCT01453933 Phase 4 raltegravir
27 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
28 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
29 The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Unknown status NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
30 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
31 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
32 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
33 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
34 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
35 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
36 An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) Completed NCT02184078 Phase 4 Nevirapine;Rifabutin
37 Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study Completed NCT00385645 Phase 4 Combivir+Kaletra;Combivir+Reyataz
38 Efficacy and Safety of Switching From AZT to Tenofovir Completed NCT00647244 Phase 4 Tenofovir disoproxil fumarate;Abacavir
39 The Optimization of HAART for Chinese——a RCT Study Completed NCT02945163 Phase 4 Tenofovir;Lamivudine;Efavirenz
40 An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®) Completed NCT02181946 Phase 4 Fluconazole;Nevirapine
41 Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients Completed NCT00466180 Phase 4
42 Comparison of Antiretroviral Activity and Immunological Effect of Two Triple Treatments With and Without Protease Inhibitors in naïve HIV-1-infected Patients With CD4 < 100/mm3 Completed NCT00385957 Phase 4 AZT+3TC+IDV+RTV;AZT+3TC+EFV
43 Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen Completed NCT00365612 Phase 4 Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
44 Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
45 A Randomised Prospective Study Assessing Changes in Neurocognitive Function, Using a Computerised Test Battery, in Treatment Naïve HIV-1 Positive Subjects Commencing Two Different Antiretroviral Regimens Completed NCT00540137 Phase 4 nevirapine;atazanavir/ritonavir
46 A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects Completed NCT01045369 Phase 4 Kaletra and Intelence Tablets
47 Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Subjects Completed NCT00116116 Phase 4 efavirenz, stavudine extended release, lamivudine
48 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4 Salvage antiretroviral therapy including raltegravir
49 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
50 Effect of Enfuvirtide on Lipid and Glucose Metabolism and Mitochondrial Function in Healthy Volunteers Completed NCT00657761 Phase 4 Enfuvirtide;Placebo

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

MalaCards organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

40
Testes, T Cells, Liver, Bone, Endothelial, Monocytes, Brain

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 6591)
# Title Authors PMID Year
1
Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). 54 61
19482361 2009
2
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. 61 54
19535523 2009
3
Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). 61 54
18546077 2008
4
Emerging antiviral drugs. 54 61
18764719 2008
5
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. 54 61
18096673 2008
6
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. 54 61
16439866 2006
7
Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. 54 61
16438645 2006
8
RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. 54 61
16353935 2005
9
Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. 54 61
14741421 2004
10
Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. 61 54
12461425 2002
11
Oral mucosal immunity and HIV infection: current status. 61 54
12164661 2002
12
Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. 61 54
11237281 2001
13
Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. 54 61
11101052 2000
14
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. 54 61
10195751 1999
15
[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]. 54 61
10189669 1999
16
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. 61 54
10231014 1999
17
Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. 61 54
9612607 1998
18
New perspectives for the treatment of HIV infections. 61 54
9646721 1998
19
The role of biological response modifiers on apoptosis in HIV infections and AIDS. 61 54
17451286 1996
20
Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. 61 54
9079375 1996
21
Zinc and immune function. 61 54
7478075 1995
22
Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. 61 54
7583919 1995
23
Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. 54 61
7946101 1994
24
[Interferon-gamma. Therapy of recurrent furunculosis in HIV infections]. 61 54
8104915 1993
25
Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion. 54 61
1492941 1992
26
Barriers to post exposure prophylaxis use among men who have sex with men in sub-Saharan Africa: An online cross-sectional survey. 61
32461879 2020
27
Architect i2000 SR has improved turnaround time for infectious disease serology testing over Vitros ECiQ. 61
32340767 2020
28
Understanding the HIV Epidemic Among MSM in Baltimore: A Modeling Study Estimating the Impact of Past HIV Interventions and Who Acquired and Contributed to Infections. 61
32141958 2020
29
Filling the gaps in the Peruvian care continuum for HIV-infected pregnant mothers: a case-control study in metropolitan Lima-Callao, Peru. 61
32487002 2020
30
Landscape of HIV Implementation Research Funded by the National Institutes of Health: A Mapping Review of Project Abstracts. 61
31845078 2020
31
HIV self-testing: The key to unlock the first 90 in West and Central Africa. 61
32070722 2020
32
[Feasibility on the Internet-based HIV nucleic acid testing with dry blood spots and risk factors associated with HIV infection in men having sex with men in Beijing]. 61
32564559 2020
33
Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico. 61
32562375 2020
34
Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population. 61
32488053 2020
35
Ending the HIV Epidemic: Contributions Resulting from Syphilis Partner Services. 61
32520880 2020
36
Update on HIV prevention and preexposure prophylaxis. 61
32384293 2020
37
Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. 61
32562365 2020
38
Estimating the impact of HIV combination prevention in men who have sex with men, the Bangkok MSM Cohort Study, Thailand. 61
32448077 2020
39
Association Between HIV-Related Tweets and HIV Incidence in the United States: Infodemiology Study. 61
32579119 2020
40
Earlier treatment initiation is associated with a decreased number of HIV-1 subtype A1 transmissions in Greece. 61
32561553 2020
41
Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure. 61
32356090 2020
42
Declining trend in HIV new infections in Guangxi, China: insights from linking reported HIV/AIDS cases with CD4-at-diagnosis data. 61
32532238 2020
43
Population Size Estimate of Men who have Sex with Men, Female Sex Workers and People who Inject Drugs in Mozambique-A multiple methods approach. 61
32530856 2020
44
Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco. 61
32494806 2020
45
[Characteristics of newly reported HIV/AIDS cases with heterosexual mode of transmission in six districts of Chongqing city]. 61
32564560 2020
46
Integrated screening and treatment services for HIV, hypertension and diabetes in Kenya: assessing the epidemiological impact and cost-effectiveness from a national and regional perspective. 61
32562353 2020
47
Understanding the costs and the cost structure of a community-based HIV and gender-based violence (GBV) prevention program: the Woza Asibonisane Community Responses Program in South Africa. 61
32522172 2020
48
Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States. 61
32492164 2020
49
Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. 61
32493720 2020
50
The Changing Profile of Paediatric HIV infection: An experience from the Middle East. 61
32526391 2020

Variations for Human Immunodeficiency Virus Infectious Disease

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Pathways for Human Immunodeficiency Virus Infectious Disease

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF IL7R IL7 IL2 IL10 IFNG
2
Show member pathways
13.85 TNF IL7R IL7 IL2 IL10 CXCR4
3
Show member pathways
13.72 TNF IL7R IL7 IL2 IL10 IFNG
4
Show member pathways
13.6 TNF IL7R IL7 IL2 IL10 IFNG
5
Show member pathways
13.48 TNF IL7R IL7 IL2 IL10 CXCR4
6
Show member pathways
13.36 TNF IL7R IL7 IL2 IL10 CXCR4
7
Show member pathways
13.36 TNF IL7R IL7 IL2 IL10 IFNG
8
Show member pathways
13.11 TNF IL2 IL10 IFNG IFNA1 CCL5
9
Show member pathways
13.02 TNF IFNA1 CXCR4 CXCL12 CD4 CCR5
10
Show member pathways
12.96 TNF IL2 IL10 IFNG IFNA1 CXCR4
11
Show member pathways
12.94 CXCR4 CXCL12 CD4 CCR5 CCL5 CCL4
12 12.9 IL7R IL7 IL2 IFNG IFNA1 CXCR4
13
Show member pathways
12.88 TNF IL2 IFNG IFNA1 CD209 CCL5
14 12.81 TNF IFNG IFNA1 CCL5 B2M
15
Show member pathways
12.68 TNF IFNG CXCR4 CD4 CCR5
16
Show member pathways
12.67 TNF IL2 IL10 IFNG CD4 CCR5
17
Show member pathways
12.65 TNF IL2 IL10 IFNG CD4
18
Show member pathways
12.62 TNF IL2 IL10 IFNG CD4
19
Show member pathways